文献速递食管与纵隔外科

放化疗、三联治疗或挽救性切除与II-III期食管鳞癌生存的关联

Association of chemoradiation, trimodality therapy, or salvage resection with survival in stage II-III esophageal squamous cell carcinoma.
PubMed 文献 · J Thorac Cardiovasc Surg · 2025-03-14

该回顾性研究基于2004-2021年美国国家癌症数据库,纳入3786例临床II-III期食管鳞癌患者,比较三联治疗、挽救性切除与根治性放化疗的生存差异。风险调整后,三联治疗和挽救性切除较根治性放化疗均与更好的1年和5年生存相关,5年限制性平均生存时间分别增加9.17个月和10.03个月。

要点

  • 放化疗后手术切除(三联或挽救)较根治性放化疗与更优生存相关
  • 三联治疗与挽救性切除的生存获益相当,部分患者或可考虑器官保留
  • 根治性放化疗在II-III期食管鳞癌中仍占多数(71%)

核心结论

  • 放化疗后手术切除与II-III期食管鳞癌患者更优的总生存相关,应被视为局部晚期食管鳞癌的主要治疗手段。
  • 三联治疗与挽救性切除的生存结果相当,部分选择患者可能适合器官保留策略。

研究设计与样本

  • 回顾性分析2004-2021年美国国家癌症数据库(National Cancer Database)。
  • 纳入所有年龄≥18岁、临床分期为II-III期的食管鳞癌患者,共3786例。
  • 三联治疗组定义为化疗联合≥41.4 Gy放射(分28次)后<90天行食管切除术;挽救性切除组为≥90天行切除术;根治性放化疗组为仅接受根治性放化疗。

主要发现

  • 3786例中,912例(24%)接受三联治疗,173例(5%)接受放化疗后挽救性切除,2701例(71%)接受根治性放化疗。
  • 风险调整后,相较根治性放化疗,三联治疗与1年生存(HR 0.45,CI 0.34-0.59)和5年生存(HR 0.57,CI 0.49-0.66)改善相关。
  • 挽救性切除同样与1年生存(HR 0.38,CI 0.22-0.69)和5年生存(HR 0.54,CI 0.40-0.73)改善相关。
  • 限制性平均生存时间分析显示,5年内三联治疗较根治性放化疗增加9.17个月(CI 6.40-11.94)总生存时间,挽救性切除增加10.03个月(CI 4.04-16.03)。

临床怎么用

  • 对于局部晚期(II-III期)食管鳞癌,放化疗后应积极评估并考虑食管切除术,以改善生存。
  • 三联治疗与挽救性切除生存相当,对部分选择患者可考虑器官保留策略,但需个体化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Esophageal squamous cell carcinoma remains highly lethal and often undertreated. With conflicting evidence regarding the additional benefit of surgical resection to chemoradiation, many patients with locoregionally advanced disease may receive chemoradiation and then undergo evaluation for progression before esophagectomy. We hypothesized that trimodality therapy or salvage resection would be linked with superior overall survival, relative to definitive chemoradiation. METHODS: This retrospective analysis of the 2004-2021 National Cancer Database identified all patients aged 18 years or more with clinically staged II-III esophageal squamous cell carcinoma. Patients undergoing chemotherapy with 41.4 Gy or more of radiation across 28 fractions, followed by esophagectomy at less than 90 days, were considered the trimodality cohort, and those undergoing resection at 90 days or more were classified as salvage. Patients receiving definitive chemoradiation were categorized as definitive chemoradiotherapy. RESULTS: Of 3786 patients, 912 (24%) underwent trimodality therapy, 173 (5%) received chemoradiation followed by salvage resection, and 2701 (71%) received definitive chemoradiotherapy. After risk adjustment and relative to definitive chemoradiotherapy, trimodality was linked with greater survival at 1 year (hazard ratio [HR], 0.45, CI, 0.34-0.59) and 5 years (HR, 0.57, CI, 0.49-0.66), as was salvage (1 year: HR, 0.38, CI, 0.22-0.69; 5 years: HR, 0.54, CI, 0.40-0.73). On restricted mean survival time analysis, trimodality demonstrated a 9.17-month (CI, 6.40-11.94) incremental increase in overall survival time over 5 years, whereas salvage was linked with a 10.03-month (CI, 4.04-16.03) increase in survival time compared with definitive chemoradiotherapy. CONCLUSIONS: Surgical resection after chemoradiation confers a survival benefit and should be considered a mainstay in the management of locoregionally advanced esophageal squamous cell carcinoma. Yet, with comparable outcomes across trimodality and salvage approaches, organ preservation may be appropriate for select patients.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Sakowitz S, Bakhtiyar SS, Mallick S, et al. Association of chemoradiation, trimodality therapy, or salvage resection with survival in stage II-III esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2025. PMID: 40090462. doi:10.1016/j.jtcvs.2025.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。